In a recent development, MBody AI Ltd., a prominent player in the health care equipment and supplies sector, has filed several beneficial ownership statements with the U.S. Securities and Exchange Commission (SEC). These filings, submitted on September 18, 2026, provide a comprehensive update on the ownership structure of the company, highlighting changes in the stakes held by its directors and officers.
MBody AI Ltd., which operates under the name Check Cap Ltd., is based in Isfiya, Israel, and specializes in the development and manufacturing of innovative medical diagnostic equipment. The company is renowned for its non-invasive device designed to detect rectal polyps. This cutting-edge technology involves a tiny sonar-like capsule that patients ingest, which then transmits data to a wrist-worn accessory. This accessory generates a three-dimensional reconstructed image of the colon, offering a significant advancement in medical diagnostics.
The company’s stock is traded on the Nasdaq stock exchange, where it has been listed since its public offering on February 19, 2015. As of September 17, 2026, the close price of MBody AI Ltd.’s stock stood at $6.39, with a 52-week high of $27.44 recorded on January 25, 2026, and a 52-week low of $6.01 on September 1, 2026. The company’s market capitalization is currently valued at $96,960,000 USD, with a price-to-earnings ratio of 270.3.
The recent SEC filings reveal a detailed picture of the company’s shareholding structure, emphasizing both direct and indirect ownership by key executives. One notable filing indicates that a director holds a direct stake in the company, while another officer possesses indirect ownership. Additionally, a director has been reported to hold a significant indirect stake through a family holding entity, encompassing several hundred thousand shares.
Further filings disclose that a director owns a small direct shareholding, with another director holding shares through a holding company. There are also reports of indirect ownership by a director through a spouse and indirect ownership by another director in a large block of shares managed by multiple investment vehicles. These filings collectively provide an updated view of the company’s top-level shareholding structure, reflecting the intricate web of direct and indirect holdings by its key executives.
As MBody AI Ltd. continues to innovate in the health care sector, these ownership changes may signal strategic shifts or reinforce the commitment of its leadership to the company’s future growth. Investors and stakeholders will undoubtedly keep a close watch on how these developments influence the company’s trajectory in the competitive landscape of medical diagnostic equipment. For more information about MBody AI Ltd.’s products and services, interested parties can visit their website at www.check-cap.com .
